View Older Stories View More Recent Stories

May 16, 2019 08:00AM Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout
May 9, 2019 08:00AM Horizon Therapeutics plc Announces Tina Ventura as a Healthcare Businesswomen's Association 2019 Luminary
May 8, 2019 07:04AM Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
Apr 26, 2019 02:01PM Horizon Pharma (HZNP) Announces New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis
Apr 26, 2019 02:00PM New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)
Apr 16, 2019 08:00AM Horizon Pharma plc and Gift of Adoption Announce a New Fund to Facilitate Global Adoptions of Children with Rare Diseases
Apr 12, 2019 08:00AM Horizon Pharma plc to Present Results from its Phase 3 Teprotumumab Trial (OPTIC) at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress
Apr 11, 2019 04:45PM Horizon Pharma plc Named One of the 2019 Best Workplaces in Health Care and Biopharma by FORTUNE and Great Place to Work®
Apr 9, 2019 04:05PM Horizon Pharma plc to Release First-Quarter 2019 Financial Results and Host Webcast on May 8, 2019
Apr 4, 2019 04:05PM Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 18, 2019 08:00AM Horizon Pharma plc Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy
Mar 1, 2019 05:50PM Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 28, 2019 07:22AM Horizon Pharma plc (HZNP) Reports Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for Treatment of Active Thyroid Eye Disease (TED) Met Primary & All Secondary Endpoints
Feb 28, 2019 07:00AM Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease (TED) Met Primary and All Secondary Endpoints
Feb 27, 2019 07:00AM Horizon Pharma plc Reports Record Fourth-Quarter and Full-Year 2018 Net Sales Driven by Orphan and Rheumatology Segment; Announces Full-Year 2019 Guidance
Feb 25, 2019 08:00AM Horizon Pharma plc to Participate in Cowen and Company 39th Annual Health Care Conference
Jan 29, 2019 08:00AM Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2018 Financial Results and Host Webcast on Feb. 27, 2019
Jan 3, 2019 08:00AM Horizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout
Dec 27, 2018 08:01AM Horizon Pharma (HZNP) Announces FDA Approval to Expand Age Range for RAVICTI Oral Liquid to Include Newborns
Dec 27, 2018 08:00AM Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Include Newborns
Dec 17, 2018 08:00AM Horizon Pharma plc to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 16, 2018 08:00AM Horizon Pharma plc to Participate in Upcoming Conferences
Nov 7, 2018 07:00AM Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance
Nov 2, 2018 09:30AM The Chicago Tribune Names Horizon Pharma plc a 2018 Top Workplace
Oct 29, 2018 05:57PM Horizon Pharma plc Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at 2018 American Academy of Ophthalmology (AAO) Annual Meeting
Oct 25, 2018 01:00PM Horizon Pharma plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates of Gout and Increased Disease Severity
Oct 25, 2018 08:00AM Horizon Pharma plc to Participate in Investor Conferences in November
Oct 22, 2018 08:00AM Horizon Pharma plc Announces Multiple Data Presentations Highlighting the Growing Burden of Uncontrolled Gout at the 2018 ACR/ARHP Annual Meeting
Oct 18, 2018 09:16AM FORTUNE and Great Place to Work® Name Horizon Pharma plc to 2018 Best Small & Medium Workplaces for Third Consecutive Year
Oct 10, 2018 08:00AM Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018
Oct 4, 2018 09:05AM HighPoint Resources (HPR) Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to Phase 2 Trial of Teprotumumab
Oct 4, 2018 09:02AM Horizon Pharma plc Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab
Sep 27, 2018 11:00AM The North American Pediatric Renal Trials and Collaborative Studies and Horizon Pharma plc Announce New Long-Term Cystinosis Registry
Sep 27, 2018 08:05AM Horizon Pharma plc (HZNP) Initiates Clinical to Evaluate KRYSTEXXA with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout
Sep 27, 2018 08:00AM Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout
Sep 25, 2018 08:00AM Horizon Pharma plc to Present 48-Week Follow-Up Analysis of the Teprotumumab Phase 2 Trial at the Annual Meeting of the American Thyroid Association
Sep 4, 2018 08:00AM Horizon Pharma plc to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference
Sep 4, 2018 07:04AM Horizon Pharma (HZNP) Completes Teprotumumab Phase 3 Enrollment Early
Sep 4, 2018 07:00AM Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
Aug 8, 2018 07:00AM Horizon Pharma plc Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment; Increases Full-Year 2018 Adjusted EBITDA Guidance; Implements New Company Operating Structure to Enhance Focu
Jul 25, 2018 09:00AM PEOPLE and Great Place to Work® Name Horizon Pharma plc to 2018 “50 Companies That Care” List
Jul 16, 2018 08:33AM UPDATE: Horizon Pharma (HZNP) Announces USPTO Issuance of Additional Notices of Allowance With Claims Covering RAVICTI Oral Liquid
Jul 16, 2018 08:30AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
Jul 9, 2018 08:30AM Horizon Pharma plc to Release Second-Quarter 2018 Financial Results and Host Webcast on August 8, 2018
Jun 15, 2018 05:49AM Horizon Pharma plc (HZNP) Highlights Multiple Analyses of KRYSTEXXA (pegloticase injection) Clinical Trial Data at EULAR 2018
Jun 15, 2018 05:45AM Horizon Pharma plc Presents Data at EULAR 2018 Advancing the Understanding and Management of Uncontrolled Gout
Jun 14, 2018 04:50AM Epidemiologic Study Findings Show 27 Percent Increase in Emergency Department Visits for Gout in the United States Over the Past Decade
Jun 4, 2018 08:00AM Horizon Pharma plc and the National Organization for Rare Disorders (NORD) Illustrate 35 years of Progress in Rare Disease at the Biotechnology Innovation Organization (BIO) International Convention
May 30, 2018 08:00AM Horizon Pharma plc to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
May 22, 2018 10:15AM Horizon Pharma plc Named One of the Best Small and Medium Workplaces in Chicago by FORTUNE
View More Recent Stories View Older Stories